Pfizer Inc

PFE

Biotechnology

Composite33/100Quality0,63Market cap136,4BIndustryBiotechnology

23.88+0.29%live quote

Data wiring in progress

Still coming: analyst coverage · calendar · peers-with-prices. Those regions are intentionally absent until wired (no fake data).

Analyst consensus

analyst directory

HOLD32 analysts

13 buy16 hold3 sell

Avg 12m price target28,97

About the company

analysis pipeline

PFIZER INC is classified under Healthcare / Biotechnology and appears profitable on the latest normalized snapshot.

Classification confidence is 0.81 based on rule-based classification; matched terms: clinical trial, pipeline.

classification: Healthcare › Biotechnology & Medical Research › Biotechnology

Analysis

as of 2026-06-09

PFIZER INC (PFE) is currently classified as Biotechnology within Biotechnology (Healthcare). Classification confidence: 0.81 (rule-based classification). Capital structure on the latest snapshot: total assets 207,618,000,000 USD, total equity 90,101,000,000, short-term debt 3,861,000,000, long-term debt 60,565,000,000. Net cash position is approximately -62,723,000,000 USD. Self-calculated market cap is 147,573,250,000 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 14,451,000,000, gross profit 0, operating income 0, net income 2,687,000,000. Return on equity ~3.0%. Return on assets ~1.3%. Operating-cash-flow to net-income ratio is 0.97. Risk profile from automated assessment: liquidity risk high, dilution risk medium. Flags: Current ratio is close to the minimum comfort range.; Net cash is negative after subtracting total debt.; Source documents mention dilution or offering risk.. Management commentary signal: purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement..

Key takeaways

Observed GAAP P/E is about 54.92x.
Return on equity is about 3.0%.
Debt to equity is about 0.72x.
Management signal detected: purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.
pfe-20260329 0000078003 12/31 2026 Q1 false one 444 225 xbrli:shares iso4217:USD iso4217:USD xbrli:shares pfe:segment pfe:payment xbrli:pure pfe:case pfe:patent pfe:complaint 0000078003 2026-01-01 2026-03-29 0000078003 us-gaap:CommonStockMember 2026-01-01 2026-03-29 0000078003 pfe:NotesDue20271.000Member 2026-01-01 2026-03-29 0000078003 pfe:NotesDue20292.875Member 2026-01-01 2026-03-29 0000078003 pfe:NotesDue20323.250Member 2026-01-01 2026-03-29 0000078003 pfe:NotesDue20373.875Member 2026-01-01 2026-03-29 0000078003 pfe:NotesDue20454.250Member 2026-01-01 2026-03-29 0000078003 2026-04-29 0000078003 us-gaap:ProductMember 2026-01-01 2026-03-29 0000078003 us-gaap:ProductMember 2025-01-01 2025-03-30 0000078003 2025-01-01 2025-03-30 0000078003 us-gaap:RoyaltyMember 2026-01-01 2026-03-29 0000078003 us-gaap:RoyaltyMember 2025-01-01 2025-03-30 0000078003 2026-03-29 0000078003 2025-12-31 0000078003 us-gaap:CommonStockMember 2025-12-31 0000078003 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000078003 us-gaap:TreasuryStockCommonMember 2025-12-31 0000078003 us-gaap:RetainedEarningsMember 2025-12-31 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0000078003 us-gaap:ParentMember 2025-12-31 0000078003 us-gaap:NoncontrollingInterestMember 2025-12-31 0000078003 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-29 0000078003 us-gaap:ParentMember 2026-01-01 2026-03-29 0000078003 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-03-29 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-29 0000078003 us-gaap:CommonStockMember 2026-01-01 2026-03-29 0000078003 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-29 0000078003 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-29 0000078003 us-gaap:CommonStockMember 2026-03-29 0000078003 us-gaap:AdditionalPaidInCapitalMember 2026-03-29 0000078003 us-gaap:TreasuryStockCommonMember 2026-03-29 0000078003 us-gaap:RetainedEarningsMember 2026-03-29 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-29 0000078003 us-gaap:ParentMember 2026-03-29 0000078003 us-gaap:NoncontrollingInterestMember 2026-03-29 0000078003 us-gaap:CommonStockMember 2024-12-31 0000078003 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000078003 us-gaap:TreasuryStockCommonMember 2024-12-31 0000078003 us-gaap:RetainedEarningsMember 2024-12-31 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000078003 us-gaap:ParentMember 2024-12-31 0000078003 us-gaap:NoncontrollingInterestMember 2024-12-31 0000078003 2024-12-31 0000078003 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-30 0000078003 us-gaap:ParentMember 2025-01-01 2025-03-30 0000078003 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-30 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-30 0000078003 us-gaap:CommonStockMember 2025-01-01 2025-03-30 0000078003 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-30 0000078003 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-30 0000078003 us-gaap:CommonStockMember 2025-03-30 0000078003 us-gaap:AdditionalPaidInCapitalMember 2025-03-30 0000078003 us-gaap:TreasuryStockCommonMember 2025-03-30 0000078003 us-gaap:RetainedEarningsMember 2025-03-30 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-30 0000078003 us-gaap:ParentMember 2025-03-30 0000078003 us-gaap:NoncontrollingInterestMember 2025-03-30 0000078003 2025-03-30 0000078003 us-gaap:AccountsReceivableMember 2026-03-29 0000078003 us-gaap:AccountsReceivableMember 2025-12-31 0000078003 us-gaap:OtherCurrentLiabilitiesMember 2026-03-29 0000078003 us-gaap:OtherCurrentLiabilitiesMember 2025-12-31 0000078003 us-gaap:OtherNoncurrentLiabilitiesMember 2026-03-29 0000078003 us-gaap:OtherNoncurrentLiabilitiesMember 2025-12-31 0000078003 pfe:MetseraMember 2025-11-13 0000078003 pfe:TotalPaymentsToFormerMetseraShareholdersMember pfe:MetseraMember 2025-11-13 0000078003 pfe:Phase3ClinicalTrialMember pfe:MetseraMember 2025-11-13 0000078003 pfe:FDAApprovalOfMET097iMember pfe:MetseraMember 2025-11-13 0000078003 pfe:FDAApprovalOfMET097iMET233iMember pfe:MetseraMember 2025-11-13 0000078003 pfe:MetseraMember 2025-11-13 2025-11-13 0000078003 pfe:SciwindBiosciencesMember pfe:InLicensingAgreementMember 2026-02-01 2026-02-28 0000078003 pfe:ViivHealthcareLimitedMember us-gaap:SubsequentEventMember 2026-03-30 0000078003 pfe:ViivHealthcareLimitedMember us-gaap:SubsequentEventMember 2026-03-31 0000078003 pfe:ViivHealthcareLimitedMember us-gaap:SubsequentEventMember 2026-03-31 2026-03-31 0000078003 pfe:RealigningOurCostBaseProgramInitialPhaseMember 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:RealigningOurCostBaseProgramInitialPhaseMember 2026-03-29 0000078003 us-gaap:OtherRestructuringMember pfe:BiopharmaSegmentMember pfe:RealigningOurCostBaseProgramResearchAndDevelopmentMember 2026-03-29 0000078003 pfe:RealigningOurCostBaseProgramMember 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:RealigningOurCostBaseProgramMember 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:RealigningOurCostBaseProgramMember 2023-10-02 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:ManufacturingOptimizationProgramPhaseOneMember 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:ManufacturingOptimizationProgramMember 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:ManufacturingOptimizationProgramMember 2024-04-01 2026-03-29 0000078003 us-gaap:OtherNonoperatingIncomeExpenseMember 2026-01-01 2026-03-29 0000078003 us-gaap:OtherNonoperatingIncomeExpenseMember 2025-01-01 2025-03-30 0000078003 us-gaap:CostOfSalesMember 2026-01-01 2026-03-29 0000078003 us-gaap:CostOfSalesMember 2025-01-01 2025-03-30 0000078003 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2026-01-01 2026-03-29 0000078003 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2025-01-01 2025-03-30 0000078003 us-gaap:ResearchAndDevelopmentExpenseMember 2026-01-01 2026-03-29 0000078003 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-03-30 0000078003 pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:RealigningOurCostBaseProgramMember 2026-01-01 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:ManufacturingOptimizationProgramMember 2026-01-01 2026-03-29 0000078003 pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:BiopharmaSegmentMember pfe:RealigningOurCostBaseProgramMember 2025-01-01 2025-03-30 0000078003 pfe:BiopharmaSegmentMember pfe:ManufacturingOptimizationProgramMember 2025-01-01 2025-03-30 0000078003 us-gaap:EmployeeSeveranceMember 2025-12-31 0000078003 pfe:AssetImpairmentsMember 2025-12-31 0000078003 us-gaap:OtherRestructuringMember 2025-12-31 0000078003 us-gaap:EmployeeSeveranceMember 2026-01-01 2026-03-29 0000078003 pfe:AssetImpairmentsMember 2026-01-01 2026-03-29 0000078003 us-gaap:OtherRestructuringMember 2026-01-01 2026-03-29 0000078003 us-gaap:EmployeeSeveranceMember 2026-03-29 0000078003 pfe:AssetImpairmentsMember 2026-03-29 0000078003 us-gaap:OtherRestructuringMember 2026-03-29 0000078003 us-gaap:InProcessResearchAndDevelopmentMember 2025-01-01 2025-03-30 0000078003 us-gaap:AccumulatedTranslationAdjustmentMember 2025-12-31 0000078003 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-12-31 0000078003 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2025-12-31 0000078003 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2025-12-31 0000078003 us-gaap:AccumulatedTranslationAdjustmentMember 2026-01-01 2026-03-29 0000078003 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2026-01-01 2026-03-29 0000078003 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2026-01-01 2026-03-29 0000078003 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2026-01-01 2026-03-29 0000078003 us-gaap:AccumulatedTranslationAdjustmentMember 2026-03-29 0000078003 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2026-03-29 0000078003 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2026-03-29 0000078003 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember 2026-03-29 0000078003 us-gaap:ShortTermInvestmentsMember 2026-03-29 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:ShortTermInvestmentsMember 2025-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2026-03-29 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2025-12-31 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:InterestRateContractMember 2026-03-29 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:InterestRateContractMember 2025-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:ForeignExchangeContractMember 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember 2025-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 pfe:LongtermInvestmentsMember 2026-03-29 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 pfe:LongtermInvestmentsMember 2025-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember pfe:LongtermInvestmentsMember 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember pfe:LongtermInvestmentsMember 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember pfe:LongtermInvestmentsMember 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember pfe:LongtermInvestmentsMember 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember pfe:LongtermInvestmentsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0000078003 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2026-03-29 0000078003 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-12-31 0000078003 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member 2026-03-29 0000078003 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember 2026-03-29 0000078003 us-gaap:ForeignGovernmentDebtSecuritiesMember 2025-12-31 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2026-03-29 0000078003 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2025-12-31 0000078003 us-gaap:CorporateDebtSecuritiesMember 2026-03-29 0000078003 us-gaap:CorporateDebtSecuritiesMember 2025-12-31 0000078003 pfe:CorporateTimeDepositsAndOtherMember 2026-03-29 0000078003 pfe:CorporateTimeDepositsAndOtherMember 2025-12-31 0000078003 us-gaap:UnsecuredDebtMember 2026-03-29 0000078003 us-gaap:UnsecuredDebtMember 2025-12-31 0000078003 us-gaap:ForeignExchangeContractMember 2026-01-01 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-03-29 0000078003 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-31 0000078003 us-gaap:DesignatedAsHedgingInstrumentMember 2026-03-29 0000078003 us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-31 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2025-12-31 0000078003 us-gaap:SalesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-03-29 0000078003 us-gaap:SalesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-31 0000078003 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2026-01-01 2026-03-29 0000078003 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-01-01 2025-03-30 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2026-01-01 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CashFlowHedgingMember 2025-01-01 2025-03-30 0000078003 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:FairValueHedgingMember 2026-01-01 2026-03-29 0000078003 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:FairValueHedgingMember 2025-01-01 2025-03-30 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2026-01-01 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:NetInvestmentHedgingMember 2025-01-01 2025-03-30 0000078003 pfe:ForeignCurrencyShortTermBorrowingsMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-01-01 2026-03-29 0000078003 pfe:ForeignCurrencyShortTermBorrowingsMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-01-01 2025-03-30 0000078003 pfe:ForeignCurrencyDebtMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-01-01 2026-03-29 0000078003 pfe:ForeignCurrencyDebtMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-01-01 2025-03-30 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2026-01-01 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2025-01-01 2025-03-30 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2026-01-01 2026-03-29 0000078003 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2025-01-01 2025-03-30 0000078003 pfe:ForeignCurrencyDebtMember 2026-03-29 0000078003 pfe:ForeignCurrencyDebtMember 2025-12-31 0000078003 us-gaap:DevelopedTechnologyRightsMember 2026-03-29 0000078003 us-gaap:DevelopedTechnologyRightsMember 2025-12-31 0000078003 us-gaap:TradeNamesMember 2026-03-29 0000078003 us-gaap:TradeNamesMember 2025-12-31 0000078003 pfe:LicensingAgreementsAndOtherMember 2026-03-29 0000078003 pfe:LicensingAgreementsAndOtherMember 2025-12-31 0000078003 us-gaap:InProcessResearchAndDevelopmentMember 2026-03-29 0000078003 us-gaap:InProcessResearchAndDevelopmentMember 2025-12-31 0000078003 pfe:LicensingAgreementsAndOtherMember 2026-03-29 0000078003 pfe:LicensingAgreementsAndOtherMember 2025-12-31 0000078003 pfe:TukysaMember us-gaap:InProcessResearchAndDevelopmentMember 2026-01-01 2026-03-29 0000078003 pfe:TukysaMember us-gaap:DevelopedTechnologyRightsMember 2026-01-01 2026-03-29 0000078003 country:US us-gaap:PensionPlansDefinedBenefitMember 2026-01-01 2026-03-29 0000078003 country:US us-gaap:PensionPlansDefinedBenefitMember 2025-01-01 2025-03-30 0000078003 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2026-01-01 2026-03-29 0000078003 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2025-01-01 2025-03-30 0000078003 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2026-01-01 2026-03-29 0000078003 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2025-01-01 2025-03-30 0000078003 pfe:VyndaqelLitigationCaseMember us-gaap:SubsequentEventMember 2026-04-01 2026-04-30 0000078003 pfe:MicroLabsChangzhouAndBioconPatentInfringementCaseMember 2026-03-01 2026-03-29 0000078003 pfe:ComirnatyMember pfe:ModernaTXUSPatentInfringementCaseMember 2022-08-01 2022-08-31 0000078003 pfe:ComirnatyMember pfe:ModernaTXUSPatentInfringementCaseMember 2024-03-01 2024-03-31 0000078003 pfe:ComirnatyMember pfe:ModernaTXUSPatentInfringementCaseMember 2025-03-01 2025-03-30 0000078003 pfe:ComirnatyMember pfe:ModernaTXEuropeanPatentInfringementCaseMember 2022-08-01 2022-08-31 0000078003 pfe:ComirnatyMember pfe:ModernaTXEuropeanPatentInfringementCaseMember 2022-09-01 2022-09-30 0000078003 pfe:ComirnatyMember pfe:ModernaTXEuropeanPatentInfringementCaseMember 2023-11-01 2023-11-30 0000078003 pfe:ComirnatyMember pfe:ModernaTXEuropeanPatentInfringementCaseMember 2024-07-01 2024-07-31 0000078003 pfe:ComirnatyMember pfe:ArbutusAndGenevantUSPatentInfringementCaseMember 2023-04-01 2023-04-30 0000078003 pfe:ComirnatyMember pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember 2024-04-01 2024-04-30 0000078003 pfe:ComirnatyMember pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember 2024-08-01 2024-08-31 0000078003 pfe:ComirnatyMember pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCIrelandPatentInfringementCaseMember 2025-07-01 2025-07-31 0000078003 pfe:ComirnatyMember pfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUnifiedPatentCourtPatentInfringementCaseMember 2025-07-01 2025-07-31 0000078003 us-gaap:PendingLitigationMember pfe:GreenstoneAntitrustLitigationMember 2020-12-31 0000078003 us-gaap:OperatingSegmentsMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 us-gaap:OperatingSegmentsMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 us-gaap:CorporateNonSegmentMember 2026-01-01 2026-03-29 0000078003 us-gaap:CorporateNonSegmentMember 2025-01-01 2025-03-30 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember 2026-01-01 2026-03-29 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember 2025-01-01 2025-03-30 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsAcquisitionRelatedCostsMember 2026-01-01 2026-03-29 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsAcquisitionRelatedCostsMember 2025-01-01 2025-03-30 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsOtherMember 2026-01-01 2026-03-29 0000078003 us-gaap:MaterialReconcilingItemsMember pfe:ReconcilingItemsOtherMember 2025-01-01 2025-03-30 0000078003 us-gaap:CorporateNonSegmentMember us-gaap:ReclassificationOtherMember 2025-01-01 2025-03-30 0000078003 pfe:ViivHealthcareLimitedMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:ViivHealthcareLimitedMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 country:US 2026-01-01 2026-03-29 0000078003 country:US 2025-01-01 2025-03-30 0000078003 pfe:InternationalDevelopedMarketsMember 2026-01-01 2026-03-29 0000078003 pfe:InternationalDevelopedMarketsMember 2025-01-01 2025-03-30 0000078003 pfe:InternationalEmergingMarketsMember 2026-01-01 2026-03-29 0000078003 pfe:InternationalEmergingMarketsMember 2025-01-01 2025-03-30 0000078003 pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:EliquisMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:EliquisMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:PrevnarPrevenarFamilyMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:PrevnarPrevenarFamilyMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:NurtecODTVyduraMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:NurtecODTVyduraMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:ComirnatyMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:ComirnatyMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:PaxlovidEUALabeledMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:PaxlovidEUALabeledMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:AbrysvoMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:AbrysvoMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:FSMEIMMUNTicoVacMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:FSMEIMMUNTicoVacMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:OtherPrimaryCareProductsMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:OtherPrimaryCareProductsMember pfe:PrimaryCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:IbranceMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:IbranceMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:PadcevMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:PadcevMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:XtandiMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:XtandiMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:LorbrenaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:LorbrenaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:InlytaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:InlytaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:AdcetrisMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:AdcetrisMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:BraftoviMektoviMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:BraftoviMektoviMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:BosulifMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:BosulifMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:TukysaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:TukysaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:OrgovyxMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:OrgovyxMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:ElrexfioMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:ElrexfioMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:TalzennaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:TalzennaMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:TivdakMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:TivdakMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:OtherOncologyProductsMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:OtherOncologyProductsMember pfe:OncologyMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:VyndaqelMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:VyndaqelMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:XeljanzMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:XeljanzMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:ZaviceftaMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:ZaviceftaMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:EnbrelMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:EnbrelMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:OctagamMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:OctagamMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:GenotropinMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:GenotropinMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:CibinqoMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:CibinqoMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:OtherSpecialtyCareMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:OtherSpecialtyCareMember pfe:SpecialtyCareMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:OncologyBiosimilarsMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:OncologyBiosimilarsMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:SulperazonMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:SulperazonMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:InflectraMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:InflectraMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:ZithromaxZmaxMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:ZithromaxZmaxMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:AllOtherHospitalAndBiosimilarsMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2026-01-01 2026-03-29 0000078003 pfe:AllOtherHospitalAndBiosimilarsMember pfe:HospitalAndBiosimilarsMember pfe:BiopharmaSegmentMember 2025-01-01 2025-03-30 0000078003 pfe:PfizerCentreOneMember 2026-01-01 2026-03-29 0000078003 pfe:PfizerCentreOneMember 2025-01-01 2025-03-30 0000078003 pfe:BiopharmaSegmentMember pfe:U.S.CommercialDivisionMember 2026-01-01 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:U.S.CommercialDivisionMember 2025-01-01 2025-03-30 0000078003 pfe:BiopharmaSegmentMember pfe:InternationalCommercialDivisionMember 2026-01-01 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:InternationalCommercialDivisionMember 2025-01-01 2025-03-30 0000078003 pfe:BiopharmaSegmentMember pfe:GlobalHospitalAndBiosimilarsDivisionMember 2026-01-01 2026-03-29 0000078003 pfe:BiopharmaSegmentMember pfe:GlobalHospitalAndBiosimilarsDivisionMember 2025-01-01 2025-03-30 0000078003 pfe:TotalAllianceBiopharmaceuticalsMember 2026-01-01 2026-03-29 0000078003 pfe:TotalAllianceBiopharmaceuticalsMember 2025-01-01 2025-03-30 0000078003 pfe:ComirnatyMember 2026-03-29 0000078003 pfe:PaxlovidMember 2026-03-29 0000078003 pfe:PaxlovidAndComirnatyMember pfe:GovernmentAndGovernmentSponsoredMember 2026-03-29 0000078003 pfe:PaxlovidAndComirnatyMember pfe:GovernmentAndGovernmentSponsoredMember 2025-12-31 0000078003 pfe:PaxlovidAndComirnatyMember pfe:GovernmentAndGovernmentSponsoredMember 2026-01-01 2026-03-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.
AND SUBSIDIARY COMPANIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Three Months Ended (MILLIONS) March 29, 2026 March 30, 2025 Operating Activities Net income before allocation to noncontrolling interests $ 2,696 $ 2,973 Discontinued operations—net of tax ( 13 ) — Net income from continuing operations before allocation to noncontrolling interests 2,709 2,973 Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities: Depreciation and amortization 1,613 1,618 Asset write-offs and impairments 32 344 Deferred taxes ( 12 ) ( 663 ) Share-based compensation expense 272 170 Benefit plan contributions in excess of expense/income ( 173 ) ( 229 ) Other adjustments, net ( 93 ) 40 Other changes in assets and liabilities, net of acquisitions and divestitures ( 1,732 ) ( 1,919 ) Net cash provided by/(used in) operating activities 2,615 2,335 Investing Activities Purchases of property, plant and equipment ( 436 ) ( 564 ) Purchases of short-term investments ( 2,569 ) ( 2,823 ) Proceeds from redemptions/sales of short-term investments 4,576 3,955 Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less ( 792 ) ( 3,852 ) Purchases of long-term investments ( 104 ) ( 134 ) Proceeds from redemptions/sales of long-term investments 88 82 Proceeds from sales of investment in Haleon — 6,311 Other investing activities, net 22 300 Net cash provided by/(used in) investing activities 785 3,274 Financing Activities Payments on short-term borrowings — ( 2,048 ) Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less ( 127 ) ( 386 ) Cash dividends paid ( 2,445 ) ( 2,437 ) Other financing activities, net ( 284 ) ( 356 ) Net cash provided by/(used in) financing activities ( 2,856 ) ( 5,227 ) Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents 19 ( 7 ) Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents 563 375 Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period 1,197 1,107 Cash and cash equivalents and restricted cash and cash equivalents, at end of period $ 1,760 $ 1,481 Supplemental Cash Flow Information Cash paid during the period for: Income taxes $ 72 $ 152 Interest paid 293 353 Interest rate hedges 62 74 See Accompanying Notes.

analysis generated 2026-06-09 · underlying data as of 2026-06-09

Valuation summary

analysis pipeline

Market cap

$147.57B

Enterprise value

$210.30B

P/E

54.9

EV/Revenue

14.6

Net margin

18.6%

ROE

3.0%

ROA

1.3%

Debt/Equity

0.7

Current ratio

1.2

Net cash

-$62.72B

Financial highlights

Q1 2026 · USD

Revenue	$14.45B
Net income	$2.69B
Operating cash flow	$2.62B
Capital expenditure	$436.0M
Free cash flow	$2.18B
Cash & equivalents	$1.70B
Total assets	$207.62B
Total liabilities	$117.21B
Total equity	$90.10B
Long-term debt	$60.56B

Risk flags

analysis pipeline

Dilution risk: mediumLiquidity risk: high

Key flags

Current ratio is close to the minimum comfort range.
Net cash is negative after subtracting total debt.
Source documents mention dilution or offering risk.

Segments & product-family mix

· segment data: live ha-ap-read-svc

Vaccines—

low · business_description · 2026-07-03

Branded / Innovative Medicines—

low · business_description · 2026-07-03

Biologics—

low · business_description · 2026-07-03

Market position

Coming soon — competitive positioning (% of segment by revenue, rank #R of P peers) lands with the layer-revenue-aggregation ingestion.

INDEX & Funds

Coming soon — index- and fund-membership data (holdings, allocation history, likely inclusions, rebalancing events) lands with the Index & Funds ingestion.

Recent in newsroom

0 articles

No recent newsroom coverage mentioning PFE.